Literature DB >> 788761

Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.

G M Pacifici, M Nardini, P Ferrari, R Latini, C Fieschi, P L Morselli.   

Abstract

Amantadine, administered at a dose of 200 mg/day, antagonized the extapyramidal symptomatology induced by neuroleptic drugs in fifteen psychiatric patients. Steady-state levels were reached within 4-7 days of treatment. Individual plasma levels ranged from 200-900 ng/ml. Apparent plasma half-lives varied from 10-28.5 h with an apparent VD of 200-400 litres. A significant relationship was found between the plasma levels of amantadine and the effects on the extrapyramidal symptomatology. The data suggest a direct effect of amantadine on dopaminergic receptors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788761      PMCID: PMC1428941          DOI: 10.1111/j.1365-2125.1976.tb00642.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Treatment of parkinsonism by amantadine and levodopa.

Authors:  C Mawdsley; I R Williams; I A Pullar; D L Davidson; N E Kinloch
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

2.  On the mode of action of amantadine.

Authors:  U Stromberg; T H Svensson; B Waldeck
Journal:  J Pharm Pharmacol       Date:  1970-12       Impact factor: 3.765

3.  Combined treatment of parkinsonism with L-dopa and amantadine.

Authors:  K R Hunter; G M Stern; D R Laurence; P Armitage
Journal:  Lancet       Date:  1970-09-12       Impact factor: 79.321

4.  Amantadine in parkinsonism.

Authors:  K R Hunter; G M Stern; D R Laurence; P Armitage
Journal:  Lancet       Date:  1970-05-30       Impact factor: 79.321

5.  Amantadine may stimulate dopamine and noradrenaline receptors.

Authors:  R Papeschi
Journal:  Neuropharmacology       Date:  1974-01       Impact factor: 5.250

6.  Comparison of amantadine, placebo, and levodopa in Parkinson's disease.

Authors:  R B Bauer; J T McHenry
Journal:  Neurology       Date:  1974-08       Impact factor: 9.910

7.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

8.  Proceedings: The effect of amantadine on the turnover of catecholamines in the rat brain.

Authors:  F Brown; P H Redfern
Journal:  J Pharm Pharmacol       Date:  1974-12       Impact factor: 3.765

9.  Amantadine versus L-2 dopa and amatadine plus L-dopa.

Authors:  C Fieschi; M Nardini; M Casacchia; M E Tedone; M Reitano; E Robotti
Journal:  Lancet       Date:  1970-07-18       Impact factor: 79.321

10.  A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).

Authors:  E M Merrick; P P Schmitt
Journal:  Curr Ther Res Clin Exp       Date:  1973-08
View more
  8 in total

1.  Toxic effects of amantadine in patients with renal failure.

Authors:  T S Ing; J T Daugirdas; L S Soung; H L Klawans; S D Mahurkar; J A Hayashi; W P Geis; J E Hano
Journal:  Can Med Assoc J       Date:  1979-03-17       Impact factor: 8.262

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

3.  Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations.

Authors:  M Brenner; A Haass; P Jacobi; K Schimrigk
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

4.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 5.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

6.  Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics.

Authors:  F G Hayden; H E Hoffman; D A Spyker
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of amantadine hydrochloride.

Authors:  F Y Aoki; D S Sitar
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

Review 8.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.